(NASDAQ: ILMN) Illumina's forecast annual revenue growth rate of 2.99% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Illumina's revenue in 2025 is $4,288,000,000.On average, 24 Wall Street analysts forecast ILMN's revenue for 2025 to be $667,888,800,000, with the lowest ILMN revenue forecast at $639,468,000,000, and the highest ILMN revenue forecast at $690,656,000,000. On average, 24 Wall Street analysts forecast ILMN's revenue for 2026 to be $681,793,600,000, with the lowest ILMN revenue forecast at $644,816,000,000, and the highest ILMN revenue forecast at $709,603,200,000.
In 2027, ILMN is forecast to generate $720,299,200,000 in revenue, with the lowest revenue forecast at $675,070,400,000 and the highest revenue forecast at $763,694,400,000.